Sanctuary Advisors LLC Cuts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Sanctuary Advisors LLC decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 26.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 17,379 shares of the medical research company’s stock after selling 6,293 shares during the period. Sanctuary Advisors LLC’s holdings in Charles River Laboratories International were worth $3,402,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund increased its position in shares of Charles River Laboratories International by 1.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock valued at $914,000 after acquiring an additional 45 shares during the last quarter. Empirical Finance LLC increased its position in shares of Charles River Laboratories International by 4.2% during the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after purchasing an additional 53 shares during the last quarter. American Trust raised its stake in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after purchasing an additional 54 shares during the period. Tortoise Investment Management LLC raised its stake in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after purchasing an additional 57 shares during the period. Finally, OLD National Bancorp IN boosted its holdings in shares of Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after buying an additional 59 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CRL shares. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. UBS Group raised their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, TD Cowen upped their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $214.00.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $190.06 on Tuesday. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The stock’s 50-day simple moving average is $194.37 and its 200 day simple moving average is $202.82. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market capitalization of $9.72 billion, a price-to-earnings ratio of 23.79, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the firm posted $2.72 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).